3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
11
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Carcinoma, Merkel Cell
2
Squamous Cell Carcinoma of Head and Neck
1
Peritoneal Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Cutaneous
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Carcinoma, Ductal, Breast
1
Carcinoma, Ductal
1
Carcinoma, Basal Cell
1
Advanced Non CNS Tumors
1
Adenocarcinoma
1
Interventions
Sorafenib
121
Nivolumab
36
pembrolizumab
32
Bevacizumab
28
lenvatinib
27
Doxorubicin
23
Radiosurgery
21
Radiofrequency Ablation
20
Oxaliplatin
20
Hepatectomy
18
Fluorouracil
15
Capecitabine
15
Magnetic Resonance Spectroscopy
14
atezolizumab
13
Leucovorin
13
Cisplatin
13
Gemcitabine
11
Erlotinib Hydrochloride
11
tislelizumab
9
Sirolimus
9
Radiotherapy
9
Irinotecan
9
Ipilimumab
9
cabozantinib
8
Liver Transplantation
8
regorafenib
7
Ramucirumab
7
Folfox protocol
7
Embolization, Therapeutic
7
sintilimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Hepatocellular
×
talimogene laherparepvec
×
Clear all
NCT02509507
2024-08-06
MASTERKEY-318
Amgen
Phase 1/2
Completed
127 enrolled
37 charts